SAN DIEGO and TAICANG, SUZHOU, China, Nov. 9, 2020 /PRNewswire/ -- Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune and inflammatory diseases, today announced that Zheng Wei, Co-Founder & CEO of Connect Biopharma, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 1:10 pm EST / 6:10 pm GMT.
About Connect Biopharma
Connect Biopharma is a U.S.- and China-based clinical-stage biopharmaceutical company, focused on the discovery and development of next-generation immune modulators to be used in the treatment of serious autoimmune and inflammatory diseases. Leveraging our expertise in the biology of T cell modulation and our proprietary Immune Modulation Technology Platform, a high-throughput screening platform that rapidly and efficiently identifies molecules that target clinically validated disease pathways, we are a company passionate about developing innovative medicines and improving the lives of those suffering from these chronic and debilitating diseases worldwide.
In addition to our lead drug candidates, CBP-201 and CBP-307, we are also advancing three preclinical programs, comprising two small molecule candidates (CBP-174 and CBP-312) and one antibody targeting IL-33 (CBP-233) as treatments for various serious inflammatory conditions. We hold all global rights to our proprietary pipeline and discovery technologies. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com
Lazar FINN Partners
David Carey (IR)
T: +1-(212) 867-1768
Erich Sandoval (Media)
+1-(646) 871-8482 or +1-(917) 497-2867
SOURCE Connect Biopharmaceuticals